DEVELOPMENT AND VALIDATION OF RP - HPLC METHOD FOR ESTIMATION OF DAPAGLIFLOZIN AND SPIRONOLACTONE IN SYNTHETIC MIXTURE

Authors

  • Ketul Gajjar, Dr. Neha Tiwari, Dr. Pragnesh Patani Author

DOI:

https://doi.org/10.48047/gwhq9f47

Keywords:

Dapagliflozin, Spironolactone, Diabetes, Hypertension, RP - HPLC method, pharmaceutical analysis

Abstract

This research article outlines the development and validation of a dependable reverse-phase highperformance liquid chromatography (RP-HPLC) method intended for the simultaneous analysis of Dapagliflozin and Spironolactone in a synthetic mixture

Downloads

Download data is not yet available.

References

Zinman, B., et al. (2015). Canagliflozin, an SGLT2 inhibitor, versus placebo in type 2 diabetes. New England Journal of Medicine, 373(3), 211-222.

Wiviott, S. D., et al. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380(4), 347-357.

Downloads

Published

2024-12-03

Issue

Vol. 53 No. 03 (2024): Year 2024, Volume 53, Issue 3

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

How to Cite

DEVELOPMENT AND VALIDATION OF RP - HPLC METHOD FOR ESTIMATION OF DAPAGLIFLOZIN AND SPIRONOLACTONE IN SYNTHETIC MIXTURE (K. G. D. N. T. Dr. Pragnesh Patani , Trans.). (2024). Cuestiones De Fisioterapia, 53(03), 4273-4306. https://doi.org/10.48047/gwhq9f47